Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
العنوان: | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma |
---|---|
المؤلفون: | Sabeen Mekan, Philippe Barthélémy, Marc-Oliver Grimm, Bohuslav Melichar, Allen C. Chen, Robert E. Hawkins, David F. McDermott, Christian Kollmannsberger, Brian I. Rini, M. Brent McHenry, Megan Wind-Rotolo, Sergio Bracarda, Nizar M. Tannir, Carlos H. Barrios, Toni K. Choueiri, Camillo Porta, Osvaldo Arén Frontera, Bernard Escudier, Robert J. Motzer, Yoshihiko Tomita, Justin Doan, Howard Gurney, V. Neiman, Frede Donskov, Alain Ravaud, Pamela Salman, Hans J. Hammers, Daniel Castellano, Thomas Powles, Saby George, Elizabeth R. Plimack, Padmanee Sharma |
المساهمون: | Hospital Universitario 12 de Octubre, Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University |
المصدر: | CheckMate 214 Investigators 2018, ' Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290 . https://doi.org/10.1056/NEJMoa1712126Test Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid NEW ENGLAND JOURNAL OF MEDICINE |
سنة النشر: | 2018 |
مصطلحات موضوعية: | 0301 basic medicine, Anticuerpos Monoclonales, Male, Indoles, MULTICENTER, Supervivencia sin Enfermedad, urologic and male genital diseases, THERAPY, 0302 clinical medicine, Antineoplastic Agents, Immunological, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Sunitinib, Tasa de Supervivencia, Ipilimumab/administration & dosage, Masculino, Aged, 80 and over, Persona de Mediana Edad, KIDNEY CANCER, Adulto, Antibodies, Monoclonal, PHASE-III TRIAL, General Medicine, Indoles/administration & dosage, Middle Aged, OPEN-LABEL, Kidney Neoplasms, Humanos, Axitinib, Survival Rate, Kidney Neoplasms/drug therapy, Nivolumab, 030220 oncology & carcinogenesis, Antineoplásicos Inmunológicos, medicine.drug, Protocolos de Quimioterapia Combinada Antineoplásica, Adult, Risk, medicine.medical_specialty, Análisis de Supervivencia, Anciano, Urology, Ipilimumab, Riesgo, Antibodies, Monoclonal/administration & dosage, Disease-Free Survival, PAZOPANIB, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Syöpätaudit - Cancers, medicine, Carcinoma, Humans, Pyrroles, SYMPTOM INDEX, Carcinoma de Células Renales, Survival rate, Carcinoma, Renal Cell, Survival analysis, Aged, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Pyrroles/administration & dosage, UNTREATED MELANOMA, medicine.disease, Pirroles, Survival Analysis, Anciano de 80 o más Años, 1ST-LINE TREATMENT, 030104 developmental biology, Carcinoma, Renal Cell/drug therapy, Quality of Life, Calidad de Vida, INTERFERON-ALPHA, business, Neoplasias Renales |
الوصف: | BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk.RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; PCONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .). |
وصف الملف: | application/pdf; fulltext |
اللغة: | English |
تدمد: | 0028-4793 1533-4406 |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be20ad4dc575b4b2b082a5f7053e6c4Test https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinomaTest(9d613da7-a490-4e1e-940a-79cc1309b512).html |
حقوق: | OPEN |
رقم الانضمام: | edsair.doi.dedup.....7be20ad4dc575b4b2b082a5f7053e6c4 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 00284793 15334406 |
---|